A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer

Wan, Fang; Chen, Xin; Dong, Li-Fan; Cheng, Yue-Hong; Long, Jing-Pei

추천

검색

자료유형: 학술저널

저자정보: Wan, Fang (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University) Chen, Xin (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University) Dong, Li-Fan (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University) Cheng, Yue-Hong (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University) Long, Jing-Pei (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제11호

발행연도: 2014.1

수록면: 4,567 - 4,570 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: This systemic analysis was conducted to evaluate the efficacy and safety of pemetrexed based chemotherapy in treating patients with metastatic breast cancer as first or second line chemotherapy. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with breast cancer were identified using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: In first line pemetrexed based regimens, 10 clinical studies which including 513 patients with advanced breast cancer were considered eligible for inclusion. For second line pemetrexed based chemotherapy, 5 clinical studies which including 281 patients with advanced breast cancer were considered eligible. Systemic analysis suggested that, in all patients, pooled RR was 32.6% (167/513) in pemetrexed based first line regimens, and 13.9 % (39/281) in pemetrexed based second line regimens. Major adverse effects were neutropenia, leukopenia, fatigue, and anemia in pemetrexed based first line treatment; and lymphopenia, neutropenia, leukopenia, as well as anemia in second line chemotherapy. One treatment related death occurred with pemetrexed based second line treatment. Conclusion: This systemic analysis suggests that pemetrexed based first line regimens are associated with a reasonable response rate and acceptable toxicity, however with low response rate for treating patients with metastatic breast cancer when is used in the second line.

#Pemetrexed #breast cancer

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요